These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 23677911)

  • 1. Aspirin Half Maximal Inhibitory Concentration Value on Platelet Cyclooxygenase1 in Severe Type-2 Diabetes Mellitus is not Significantly Different from that of Healthy Individuals.
    Kimura Y; Takano K; Satoh K; Aida K; Kobayashi T; Ozaki Y
    Clin Appl Thromb Hemost; 2014 Sep; 20(6):629-36. PubMed ID: 23677911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term exposure of platelets to glucose impairs inhibition of platelet aggregation by cyclooxygenase inhibitors.
    Kobzar G; Mardla V; Samel N
    Platelets; 2011; 22(5):338-44. PubMed ID: 21557683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes.
    Rocca B; Santilli F; Pitocco D; Mucci L; Petrucci G; Vitacolonna E; Lattanzio S; Mattoscio D; Zaccardi F; Liani R; Vazzana N; Del Ponte A; Ferrante E; Martini F; Cardillo C; Morosetti R; Mirabella M; Ghirlanda G; Davì G; Patrono C
    J Thromb Haemost; 2012 Jul; 10(7):1220-30. PubMed ID: 22471290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin.
    Guthikonda S; Lev EI; Patel R; DeLao T; Bergeron AL; Dong JF; Kleiman NS
    J Thromb Haemost; 2007 Mar; 5(3):490-6. PubMed ID: 17319904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy.
    Guthikonda S; Mangalpally K; Vaduganathan M; Patel R; Delao T; Bergeron AL; Dong JF; Lev EI; Kleiman NS
    Thromb Haemost; 2008 Jul; 100(1):83-9. PubMed ID: 18612542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients.
    Ohmori T; Yatomi Y; Nonaka T; Kobayashi Y; Madoiwa S; Mimuro J; Ozaki Y; Sakata Y
    J Thromb Haemost; 2006 Jun; 4(6):1271-8. PubMed ID: 16706971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
    Gurbel PA; Bliden KP; DiChiara J; Newcomer J; Weng W; Neerchal NK; Gesheff T; Chaganti SK; Etherington A; Tantry US
    Circulation; 2007 Jun; 115(25):3156-64. PubMed ID: 17562955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variable platelet response to aspirin in patients with ischemic stroke.
    Hohlfeld T; Weber AA; Junghans U; Schumacher M; Boucher M; Schrör K; Siebler M
    Cerebrovasc Dis; 2007; 24(1):43-50. PubMed ID: 17519543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance".
    Santilli F; Rocca B; De Cristofaro R; Lattanzio S; Pietrangelo L; Habib A; Pettinella C; Recchiuti A; Ferrante E; Ciabattoni G; Davì G; Patrono C
    J Am Coll Cardiol; 2009 Feb; 53(8):667-77. PubMed ID: 19232899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suboptimal inhibition of platelet cyclooxygenase-1 by aspirin in metabolic syndrome.
    Smith JP; Haddad EV; Taylor MB; Oram D; Blakemore D; Chen Q; Boutaud O; Oates JA
    Hypertension; 2012 Mar; 59(3):719-25. PubMed ID: 22311905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin.
    Pettinella C; Romano M; Stuppia L; Santilli F; Liani R; Davì G
    Thromb Haemost; 2009 Apr; 101(4):687-90. PubMed ID: 19350112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of gallic acid, resveratrol, quercetin and aspirin at the platelet cyclooxygenase-1 level. Functional and modelling studies.
    Crescente M; Jessen G; Momi S; Höltje HD; Gresele P; Cerletti C; de Gaetano G
    Thromb Haemost; 2009 Aug; 102(2):336-46. PubMed ID: 19652885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New direct and indirect methods for the detection of cyclooxygenase 1 acetylation by aspirin; the lack of aspirin resistance among healthy individuals.
    Kovács EG; Katona E; Bereczky Z; Homoródi N; Balogh L; Tóth E; Péterfy H; Kiss RG; Edes I; Muszbek L
    Thromb Res; 2013 Apr; 131(4):320-4. PubMed ID: 23422285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Residual cyclooxygenase-1 activity and epinephrine reduce the antiplatelet effect of aspirin in patients with acute myocardial infarction.
    Moscardó A; Santos MT; Fuset MP; Ruano M; Vallés J
    Thromb Haemost; 2011 Apr; 105(4):663-9. PubMed ID: 21301784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin D diminishes the high platelet aggregation of type 2 diabetes mellitus patients.
    Sultan M; Twito O; Tohami T; Ramati E; Neumark E; Rashid G
    Platelets; 2019; 30(1):120-125. PubMed ID: 29313404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial.
    Angiolillo DJ; Hwang C; Datto C; Desai B; Sostek M
    Clin Ther; 2011 Dec; 33(12):1883-93. PubMed ID: 22078153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to low-dose aspirin therapy among patients with acute coronary syndrome in relation to associated risk factors.
    Salama MM; Morad AR; Saleh MA; Sabri NA; Zaki MM; ElSafady LA
    J Clin Pharm Ther; 2012 Dec; 37(6):630-6. PubMed ID: 23121257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease.
    Sciulli MG; Renda G; Capone ML; Tacconelli S; Ricciotti E; Manarini S; Evangelista V; Rebuzzi A; Patrignani P
    Clin Pharmacol Ther; 2006 Aug; 80(2):115-25. PubMed ID: 16890573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA.
    McCabe DJ; Harrison P; Mackie IJ; Sidhu PS; Lawrie AS; Purdy G; Machin SJ; Brown MM
    Platelets; 2005 Aug; 16(5):269-80. PubMed ID: 16011977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of laboratory methods routinely used to detect the effect of aspirin against new reference methods.
    Kovács EG; Katona É; Bereczky Z; Homoródi N; Balogh L; Tóth E; Péterfy H; Kiss RG; Édes I; Muszbek L
    Thromb Res; 2014 May; 133(5):811-6. PubMed ID: 24207016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.